Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back
出版年份 2014 全文链接
标题
Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back
作者
关键词
-
出版物
CA-A CANCER JOURNAL FOR CLINICIANS
Volume 64, Issue 6, Pages 422-444
出版商
American Cancer Society
发表日期
2014-09-30
DOI
10.3322/caac.21252
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- How we manage autologous stem cell transplantation for patients with multiple myeloma
- (2014) M. A. Gertz et al. BLOOD
- Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results
- (2014) Graham H. Jackson et al. BRITISH JOURNAL OF HAEMATOLOGY
- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Best Treatment Strategies in High-Risk Multiple Myeloma: Navigating a Gray Area
- (2014) Giada Bianchi et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination of International Scoring System 3, High Lactate Dehydrogenase, and t(4;14) and/or del(17p) Identifies Patients With Multiple Myeloma (MM) Treated With Front-Line Autologous Stem-Cell Transplantation at High Risk of Early MM Progression–Related Death
- (2014) Philippe Moreau et al. JOURNAL OF CLINICAL ONCOLOGY
- Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data
- (2014) Antonio Palumbo et al. LANCET ONCOLOGY
- Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
- (2014) Lotfi Benboubker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
- (2014) Niccolo Bolli et al. Nature Communications
- Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
- (2014) D S Siegel et al. Blood Cancer Journal
- Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management
- (2013) S. Vincent Rajkumar AMERICAN JOURNAL OF HEMATOLOGY
- Trends in Use of and Survival after Autologous Hematopoietic Cell Transplantation in North America, 1995-2005: Significant Improvement in Survival for Lymphoma and Myeloma during a Period of Increasing Recipient Age
- (2013) Philip L. McCarthy et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Hematopoietic Cell Transplant Comorbidity Index Is Predictive of Survival after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma
- (2013) Ayman Saad et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02
- (2013) X. Leleu et al. BLOOD
- A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance
- (2013) Z. Tian et al. BLOOD
- PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma
- (2013) P. G. Richardson et al. BLOOD
- Carfilzomib
- (2013) K. M. Kortuem et al. BLOOD
- Genomic instability in multiple myeloma: mechanisms and therapeutic implications
- (2013) Paola Neri et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma
- (2013) Prashant Kapoor et al. JOURNAL OF CLINICAL ONCOLOGY
- International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease
- (2013) Evangelos Terpos et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma
- (2013) Jesús F. San-Miguel et al. JOURNAL OF CLINICAL ONCOLOGY
- Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study
- (2013) Andy C. Rawstron et al. JOURNAL OF CLINICAL ONCOLOGY
- Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study
- (2013) Meletios Dimopoulos et al. LANCET ONCOLOGY
- Inhibition of HSP90 molecular chaperones: moving into the clinic
- (2013) Rocio Garcia-Carbonero et al. LANCET ONCOLOGY
- Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study
- (2013) A J Jakubowiak et al. LEUKEMIA
- Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients
- (2013) A K Nooka et al. LEUKEMIA
- Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms
- (2013) B A Walker et al. LEUKEMIA
- Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
- (2013) J. Kronke et al. SCIENCE
- The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
- (2013) G. Lu et al. SCIENCE
- Novel Agents for Multiple Myeloma to Overcome Resistance in Phase III Clinical Trials
- (2013) Robert Z. Orlowski SEMINARS IN ONCOLOGY
- A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
- (2012) D. S. Siegel et al. BLOOD
- IMWG consensus on maintenance therapy in multiple myeloma
- (2012) H. Ludwig et al. BLOOD
- A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide
- (2012) M. A. Dimopoulos et al. BLOOD
- Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma
- (2012) P. L. Bergsagel et al. BLOOD
- Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics
- (2012) A. J. Greenberg et al. BLOOD
- Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma
- (2012) S. Kumar et al. BLOOD
- Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma
- (2012) Y.-T. Tai et al. BLOOD
- Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
- (2012) L. Santo et al. BLOOD
- Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment
- (2012) K E Armeson et al. BONE MARROW TRANSPLANTATION
- A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance
- (2012) Dharminder Chauhan et al. CANCER CELL
- Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial
- (2012) M. A. Dimopoulos et al. HAEMATOLOGICA
- Evolution of cellular immunotherapy: from allogeneic transplant to dendritic cell vaccination as treatment for multiple myeloma
- (2012) Jon Arnason et al. Immunotherapy
- The 39th David A. Karnofsky Lecture: Bench-to-Bedside Translation of Targeted Therapies in Multiple Myeloma
- (2012) Kenneth C. Anderson JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial
- (2012) Pieter Sonneveld et al. JOURNAL OF CLINICAL ONCOLOGY
- Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
- (2012) Sagar Lonial et al. JOURNAL OF CLINICAL ONCOLOGY
- High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma
- (2012) G Bianchi et al. LEUKEMIA
- Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma
- (2012) J T Larsen et al. LEUKEMIA
- Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
- (2012) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Plasma Cell Myeloma and Related Neoplasms
- (2011) Robert B. Lorsbach et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Pathogenesis of Myeloma
- (2011) Kenneth C. Anderson et al. Annual Review of Pathology-Mechanisms of Disease
- Paraproteins of familial MGUS/multiple myeloma target family-typical antigens: hyperphosphorylation of autoantigens is a consistent finding in familial and sporadic MGUS/MM
- (2011) S. Grass et al. BLOOD
- Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p
- (2011) K. Neben et al. BLOOD
- The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis
- (2011) G. J. Morgan et al. BLOOD
- International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation
- (2011) M. Cavo et al. BLOOD
- Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation
- (2011) E. Zamagni et al. BLOOD
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial
- (2011) Paul G. Richardson et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
- (2011) David H. Henry et al. JOURNAL OF CLINICAL ONCOLOGY
- Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
- (2011) Philippe Moreau et al. LANCET ONCOLOGY
- Initial genome sequencing and analysis of multiple myeloma
- (2011) Michael A. Chapman et al. NATURE
- Molecular chaperones in protein folding and proteostasis
- (2011) F. Ulrich Hartl et al. NATURE
- Diagnosis of Smoldering Multiple Myeloma
- (2011) S. Vincent Rajkumar et al. NEW ENGLAND JOURNAL OF MEDICINE
- Deubiquitinases in cancer: new functions and therapeutic options
- (2011) J M Fraile et al. ONCOGENE
- The Unfolded Protein Response: From Stress Pathway to Homeostatic Regulation
- (2011) P. Walter et al. SCIENCE
- Molecular Imaging in Myeloma Precursor Disease
- (2011) Esther Mena et al. SEMINARS IN HEMATOLOGY
- Ultra High-Risk Myeloma
- (2011) H. Avet-Loiseau Hematology-American Society of Hematology Education Program
- XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments
- (2010) T. Bagratuni et al. BLOOD
- Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma
- (2010) J. Rosenblatt et al. BLOOD
- Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug
- (2010) J. Hu et al. BLOOD
- Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma
- (2010) I. Papandreou et al. BLOOD
- Lenalidomide mode of action: linking bench and clinical findings
- (2010) Faith Davies et al. BLOOD REVIEWS
- New Molecular and Biological Mechanism of Antitumor Activities of KW-2478, a Novel Nonansamycin Heat Shock Protein 90 Inhibitor, in Multiple Myeloma Cells
- (2010) T. Nakashima et al. CLINICAL CANCER RESEARCH
- Proteostenosis and plasma cell pathophysiology
- (2010) Simone Cenci et al. CURRENT OPINION IN CELL BIOLOGY
- Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study
- (2010) Meletios A. Dimopoulos et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study
- (2010) Pierre Wijermans et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial
- (2010) Jean-Luc Harousseau et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences
- (2010) Bart Barlogie et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
- (2010) Hervé Avet-Loiseau et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial
- (2010) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group
- (2010) Meletios A. Dimopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
- (2010) M. de Weers et al. JOURNAL OF IMMUNOLOGY
- First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
- (2010) Gareth J Morgan et al. LANCET
- Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
- (2010) Michele Cavo et al. LANCET
- Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
- (2010) M Q Lacy et al. LEUKEMIA
- Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
- (2010) R A Kyle et al. LEUKEMIA
- Identification of a Primary Target of Thalidomide Teratogenicity
- (2010) T. Ito et al. SCIENCE
- How I treat multiple myeloma in younger patients
- (2009) A. K. Stewart et al. BLOOD
- A monoclonal gammopathy precedes multiple myeloma in most patients
- (2009) B. M. Weiss et al. BLOOD
- CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy
- (2009) A. K. Azab et al. BLOOD
- Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
- (2009) O. Landgren et al. BLOOD
- The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition
- (2009) G. Bianchi et al. BLOOD
- Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma
- (2009) M. Fulciniti et al. BLOOD
- Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline
- (2009) Paul G. Richardson et al. BRITISH JOURNAL OF HAEMATOLOGY
- Getting to First Base in Proteasome Assembly
- (2009) Henrike C. Besche et al. CELL
- Multiple Myeloma Bone Marrow Niche
- (2009) Grzegorz Basak et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- The bisphosphonate zoledronic acid has antimyeloma activityin vivoby inhibition of protein prenylation
- (2009) Andreas Guenther et al. INTERNATIONAL JOURNAL OF CANCER
- Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy
- (2009) Paul G. Richardson et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
- (2009) S Vincent Rajkumar et al. LANCET ONCOLOGY
- Is the international staging system superior to the Durie–Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant
- (2009) P N Hari et al. LEUKEMIA
- Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial
- (2009) C B Reeder et al. LEUKEMIA
- Breaking the chains: structure and function of the deubiquitinases
- (2009) David Komander et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
- (2009) Michael Gnant et al. NEW ENGLAND JOURNAL OF MEDICINE
- Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT
- (2009) Patrice Dubreuil et al. PLoS One
- Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis
- (2008) Shaji K. Kumar et al. AMERICAN JOURNAL OF HEMATOLOGY
- Comparison of Twin and Autologous Transplants for Multiple Myeloma
- (2008) Asad Bashey et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Multiple myeloma
- (2008) R. A. Kyle et al. BLOOD
- Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities
- (2008) B. Barlogie et al. BLOOD
- Aplidin, a Marine Organism-Derived Compound with Potent Antimyeloma Activity In vitro and In vivo
- (2008) C. S. Mitsiades et al. CANCER RESEARCH
- Mechanisms of proteasome inhibitor action and resistance in cancer
- (2008) David J. McConkey et al. DRUG RESISTANCE UPDATES
- Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study
- (2008) Asher Chanan-Khan et al. JOURNAL OF CLINICAL ONCOLOGY
- Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma
- (2008) T Stühmer et al. LEUKEMIA
- IRF4 addiction in multiple myeloma
- (2008) Arthur L. Shaffer et al. NATURE
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
- (2008) Jesús F. San Miguel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI)
- (2008) T. G. Gleeson et al. SKELETAL RADIOLOGY
- Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma
- (2007) A. Dispenzieri et al. BLOOD
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now